About this project
The problem we solve:
TowerView targets the problem of medication non-adherence. According to the WHO, 50% of patients do not take medication as directed, resulting in nearly $100B in avoidable costs an estimated 125,00 deaths per year. TowerView sells its solution on a subscription basis to healthcare organizations that are financially at-risk for patient care. These organizations provide TowerView’s service to their highest risk, highest cost patients free of charge in order to improve government mandated quality scores (e.g STAR s) and reduce hospital utilization. TowerView is the only company that has designed and integrated software, hardware, and novel, senior-focused packaging to deliver an end-to-end medication management solution for patients. With the average chronically ill patient taking 5-7 medications we believe the days of the orange medication vial are numbered and we're bringing the thoughtfully designed alternative to replace it.
About our solution:
TowerView helps chronically ill patients manage complex medication regimens. Patients using the service receive prefilled trays from our partner pharmacies that separate their medications by dose and time. These trays insert directly into our connected pillbox whose proprietary sensing technology detects missed doses and triggers automated on-box (lights and sound) and off-box (text, message, or emails). TowerView’s software platform aggregates and analyzes real time medication adherence data enabling nurses and health coaches to perform targeted outreach to address barriers to adherence. TowerView’s current market focus is the 30M+ receiving care through Medicare Advantage, Dual Eligibles, and Managed Medicaid. Additional market segments include private duty homecare and select specialty pharmacy categories such as oral oncology, MS, and Hep C. Progress to date:
TowerView is currently conducting an Independence Blue Cross-sponsored, 150 patient RCT of its solution at UPenn Medicine. The company has secured pilots in heart failure populations with Cigna Healthspring, Centene, Ascension Health, SCAN Health Plan, and Anthem. The company’s highly scalable pill-sensing technology is currently patent pending with multiple continuations expected. TowerView has raised $1.4M in seed financing, which will be leveraged to convert existing pilots to scaled contracts with payers. This should position the company well for a larger Series A financing in early 2017 in order to further expand our team and accelerate growth.
About Our Team
Mr. Nikolaos Valilis, BS (Medical Student)
Medical Student, Medical Student
McGovern School of Medicine Bio:
I'm med student turned cancer survivor turned digital health entrepreneur. After being diagnosed with AML and undergoing an allogeneic stem cell transplant in 2012, I took a leave of absence from medical school to launch TowerView Health and help the millions of Americans struggling to manage complex medication regimens.
About Our Company
TowerView Health Location:
Website: http://www.towerviewhealth.com Twitter: @TowerViewHealth Product stage: